FDA Inspection 1232731 — Exeltis USA, Inc.
The FDA completed an inspection of Exeltis USA, Inc. on Nov 15, 2024 in Florham Park, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 15, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Florham Park, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)